PT3468965T - Compostos de 1-tetra-hidropiranilcarbonil-2,3-di-hidro-1h-indole para tratamento de cancro - Google Patents
Compostos de 1-tetra-hidropiranilcarbonil-2,3-di-hidro-1h-indole para tratamento de cancroInfo
- Publication number
- PT3468965T PT3468965T PT177289907T PT17728990T PT3468965T PT 3468965 T PT3468965 T PT 3468965T PT 177289907 T PT177289907 T PT 177289907T PT 17728990 T PT17728990 T PT 17728990T PT 3468965 T PT3468965 T PT 3468965T
- Authority
- PT
- Portugal
- Prior art keywords
- tetrahydropyranylcarbonyl
- dihydro
- treating cancer
- indole compounds
- indole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662348457P | 2016-06-10 | 2016-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3468965T true PT3468965T (pt) | 2020-07-16 |
Family
ID=59031409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT177289907T PT3468965T (pt) | 2016-06-10 | 2017-05-31 | Compostos de 1-tetra-hidropiranilcarbonil-2,3-di-hidro-1h-indole para tratamento de cancro |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US9872853B2 (pt) |
| EP (1) | EP3468965B1 (pt) |
| JP (1) | JP6632746B2 (pt) |
| KR (1) | KR102241258B1 (pt) |
| CN (1) | CN109641881B (pt) |
| AR (1) | AR108586A1 (pt) |
| AU (1) | AU2017277833B2 (pt) |
| BR (1) | BR112018072872A2 (pt) |
| CA (1) | CA3027035C (pt) |
| CL (1) | CL2018003543A1 (pt) |
| CO (1) | CO2018013251A2 (pt) |
| CR (1) | CR20180579A (pt) |
| CY (1) | CY1123660T1 (pt) |
| DK (1) | DK3468965T3 (pt) |
| DO (1) | DOP2018000278A (pt) |
| EA (1) | EA037419B1 (pt) |
| EC (1) | ECSP19001734A (pt) |
| ES (1) | ES2797981T3 (pt) |
| HR (1) | HRP20200769T1 (pt) |
| HU (1) | HUE050155T2 (pt) |
| IL (1) | IL263497B (pt) |
| JO (1) | JOP20170131B1 (pt) |
| LT (1) | LT3468965T (pt) |
| MA (1) | MA45224B1 (pt) |
| MD (1) | MD3468965T2 (pt) |
| ME (1) | ME03744B (pt) |
| MX (1) | MX2018015275A (pt) |
| MY (1) | MY197462A (pt) |
| NZ (1) | NZ748500A (pt) |
| PE (1) | PE20190378A1 (pt) |
| PH (1) | PH12018502572A1 (pt) |
| PL (1) | PL3468965T3 (pt) |
| PT (1) | PT3468965T (pt) |
| RS (1) | RS60322B1 (pt) |
| SG (1) | SG11201809625RA (pt) |
| SI (1) | SI3468965T1 (pt) |
| TW (1) | TWI671294B (pt) |
| UA (1) | UA122526C2 (pt) |
| WO (1) | WO2017213919A1 (pt) |
| ZA (1) | ZA201807688B (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
| KR102398439B1 (ko) | 2016-03-07 | 2022-05-16 | 이난타 파마슈티칼스, 인코포레이티드 | B형 간염 항바이러스제 |
| WO2019046271A1 (en) | 2017-08-28 | 2019-03-07 | Enanta Pharmaceuticals, Inc. | ANTIVIRAL AGENTS AGAINST HEPATITIS B |
| WO2019089412A1 (en) * | 2017-11-01 | 2019-05-09 | Merck Sharp & Dohme Corp. | Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| US20210002371A1 (en) * | 2017-12-21 | 2021-01-07 | Brian A. Sherer | Combination of an anti-pd-l1 antibody and ido1 inhibitor for the treatment of cancer |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11992489B2 (en) | 2018-08-17 | 2024-05-28 | Merck Sharp & Dohme Llc | Substituted tetrahydroquinoline compounds as indoleamine 2,3-dioxygenase inhibitors |
| WO2020061435A1 (en) | 2018-09-21 | 2020-03-26 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| EP3877366A4 (en) * | 2018-11-06 | 2022-08-24 | Merck Sharp & Dohme Corp. | NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS AS INDOLAMINE-2,3-DIOXYGENASE INHIBITORS |
| JP2022507724A (ja) | 2018-11-21 | 2022-01-18 | エナンタ ファーマシューティカルズ インコーポレイテッド | 抗ウイルス剤としての官能化複素環 |
| WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11472808B2 (en) | 2019-06-04 | 2022-10-18 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents |
| WO2021007488A1 (en) | 2019-07-11 | 2021-01-14 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| CN114105961B (zh) * | 2021-12-10 | 2023-09-12 | 海南梵圣生物科技有限公司 | 一种ido1抑制剂(ly-3381916)制备方法 |
| CN114213310B (zh) * | 2021-12-31 | 2024-02-23 | 中国药科大学 | 吲哚啉化合物及其衍生物、制备方法、药物组合物和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1787982B1 (en) * | 2003-04-11 | 2010-05-12 | High Point Pharmaceuticals, LLC | 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds |
| BRPI0608604B8 (pt) * | 2005-05-10 | 2021-05-25 | Incyte Corp | moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica |
| US7622495B2 (en) * | 2006-10-03 | 2009-11-24 | Neurim Pharmaceuticals (1991) Ltd. | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents |
| US8536221B2 (en) * | 2008-02-07 | 2013-09-17 | Abbvie Inc. | Amide derivatives as positive allosteric modulators and methods of use thereof |
| PT2824100T (pt) * | 2008-07-08 | 2018-05-10 | Incyte Holdings Corp | 1,2,5-oxadiazoles como inibidores da indoleamina 2,3-dioxigenase |
| NO2694640T3 (pt) * | 2011-04-15 | 2018-03-17 | ||
| MA38483A1 (fr) * | 2013-03-15 | 2018-02-28 | Bristol Myers Squibb Co | Inhibiteurs de l'ido |
| PL3125883T3 (pl) * | 2014-04-04 | 2021-02-08 | Iomet Pharma Ltd. | Pochodne indolu do stosowania w medycynie |
| UY36391A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| EP3405478A4 (en) * | 2015-12-23 | 2019-10-30 | Moonshot Pharma LLC | METHOD FOR INDUCING AN IMMUNE RESPONSE BY INHIBITING NONSENSE-MEDIATED CRASH |
-
2017
- 2017-05-24 AR ARP170101413A patent/AR108586A1/es unknown
- 2017-05-24 JO JOP/2017/0131A patent/JOP20170131B1/ar active
- 2017-05-25 TW TW106117300A patent/TWI671294B/zh active
- 2017-05-31 SG SG11201809625RA patent/SG11201809625RA/en unknown
- 2017-05-31 HU HUE17728990A patent/HUE050155T2/hu unknown
- 2017-05-31 CA CA3027035A patent/CA3027035C/en active Active
- 2017-05-31 JP JP2018563823A patent/JP6632746B2/ja active Active
- 2017-05-31 PE PE2018003199A patent/PE20190378A1/es unknown
- 2017-05-31 US US15/609,115 patent/US9872853B2/en active Active
- 2017-05-31 MY MYPI2018002369A patent/MY197462A/en unknown
- 2017-05-31 CN CN201780035976.4A patent/CN109641881B/zh not_active Expired - Fee Related
- 2017-05-31 ME MEP-2020-98A patent/ME03744B/me unknown
- 2017-05-31 MX MX2018015275A patent/MX2018015275A/es unknown
- 2017-05-31 SI SI201730252T patent/SI3468965T1/sl unknown
- 2017-05-31 DK DK17728990.7T patent/DK3468965T3/da active
- 2017-05-31 AU AU2017277833A patent/AU2017277833B2/en not_active Ceased
- 2017-05-31 PL PL17728990T patent/PL3468965T3/pl unknown
- 2017-05-31 UA UAA201811735A patent/UA122526C2/uk unknown
- 2017-05-31 BR BR112018072872-1A patent/BR112018072872A2/pt not_active Application Discontinuation
- 2017-05-31 NZ NZ748500A patent/NZ748500A/en not_active IP Right Cessation
- 2017-05-31 CR CR20180579A patent/CR20180579A/es unknown
- 2017-05-31 MA MA45224A patent/MA45224B1/fr unknown
- 2017-05-31 EA EA201892479A patent/EA037419B1/ru unknown
- 2017-05-31 MD MDE20190462T patent/MD3468965T2/ro unknown
- 2017-05-31 ES ES17728990T patent/ES2797981T3/es active Active
- 2017-05-31 WO PCT/US2017/035097 patent/WO2017213919A1/en unknown
- 2017-05-31 EP EP17728990.7A patent/EP3468965B1/en active Active
- 2017-05-31 LT LTEP17728990.7T patent/LT3468965T/lt unknown
- 2017-05-31 KR KR1020187035215A patent/KR102241258B1/ko active IP Right Grant
- 2017-05-31 RS RS20200623A patent/RS60322B1/sr unknown
- 2017-05-31 PT PT177289907T patent/PT3468965T/pt unknown
- 2017-05-31 US US16/307,612 patent/US10759786B2/en active Active
-
2018
- 2018-11-15 ZA ZA2018/07688A patent/ZA201807688B/en unknown
- 2018-12-04 IL IL263497A patent/IL263497B/en active IP Right Grant
- 2018-12-06 CO CONC2018/0013251A patent/CO2018013251A2/es unknown
- 2018-12-06 PH PH12018502572A patent/PH12018502572A1/en unknown
- 2018-12-10 DO DO2018000278A patent/DOP2018000278A/es unknown
- 2018-12-10 CL CL2018003543A patent/CL2018003543A1/es unknown
-
2019
- 2019-01-09 EC ECSENADI20191734A patent/ECSP19001734A/es unknown
-
2020
- 2020-05-12 HR HRP20200769TT patent/HRP20200769T1/hr unknown
- 2020-06-05 CY CY20201100508T patent/CY1123660T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263497B (en) | 1-tetrahydropyranylcarbonyl-3,2-dihydro-h1-indole compounds for cancer treatment | |
| HK1251407A1 (zh) | 治療癌症的方法 | |
| ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| IL260444B (en) | Anti-her2 combinations for cancer treatment | |
| LT3377516T (lt) | Kompozicija vėžiui gydyti | |
| IL260442B (en) | Combinations of anti-cd20 for cancer treatment | |
| IL249229A0 (en) | Compounds for the treatment of brain cancer | |
| HK1254258A1 (zh) | 使用阿吡莫德治療癌症的方法 | |
| EP3405203A4 (en) | METHODS OF TREATING CANCER | |
| EP3389634A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
| EP3440112A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
| HK1250944A1 (zh) | 用於治療癌症的方法 | |
| GB201709405D0 (en) | Compounds for treating ovarian cancer | |
| EP3389652A4 (en) | METHODS OF TREATING CANCER | |
| HK1250942A1 (zh) | 用於治療癌症的方法 | |
| HK1250943A1 (zh) | 用於治療癌症的方法 | |
| EP3296294A4 (en) | Compound for treating or preventing breast cancer | |
| HK1259615A1 (zh) | 谷氨酸-高z元素化合物治療癌症 | |
| PT3580211T (pt) | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro | |
| AU2014904697A0 (en) | Compounds for treating cancer |